Dr. Bon-Kwon Koo and Dr. C. Michael Gibson Discuss: The FLAVOUR Randomized Clinical Trial: Comparison Of Fractional Flow Reserve-guided And Intravascular Ultrasound-guided Percutaneous Coronary Intervention In Intermediate Coronary Artery Stenosis April 4, 2022 Disclosures: TBA
Dr. Duk-Woo Park and Dr. C. Michael Gibson Discuss: A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement April 4, 2022 Disclosures: TBA
Dr. Michael Reardon and Dr. Yazan Daaboul Discuss: Insights From The Corevalve US Pivotal And SURTAVI Trials: Five-year Incidence, Timing And Predictors Of Hemodynamic Valve Deterioration Of Transcatheter And Surgical Aortic Bioprostheses April 4, 2022 Disclosures: TBA
Dr. Adam Greenbaum and Dr. Serge Korjian Discuss: One-year Results Of The Clasp TR Study: Transcatheter Treatment Of Tricuspid Regurgitation April 4, 2022 Disclosures: TBA
Dr. Maura Marcucci and Dr. Yazan Daaboul Discuss: POISE-3: The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery April 4, 2022 Disclosures: TBA
Dr. Daniel Sessler and Dr. C. Michael Gibson Discuss: The PROTECT Trial: Very Mild Perioperative Hypothermia Versus Aggressive Warming And Myocardial Injury After Non-cardiac Surgery April 4, 2022 Disclosures: TBA
Dr. Ajay Kirtane and Dr. C. Michael Gibson Discuss: ACC 2022 Wrap-Up – Sunday, April 3 April 3, 2022 Disclosures: TBA
Dr. Jose Luis Leiva Pons and Dr. Cecilia Bahit Discuss: ACC 2022 Wrap-Up in Spanish April 3, 2022 Disclosures: TBA
Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: VALOR-HCM: Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy April 3, 2022 Disclosures: TBA
Dr. Yutao Guo and Dr. Yazan Daaboul Discuss: A Report From The mAFA-II Trial Long-term Extension Cohort: Consumer-led Screening For Atrial Fibrillation April 3, 2022 Disclosures: TBA
